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Helix stabilityUbiquitin conjugation is an important signal in cellular pathways, changing the fate of a target protein, by
degradation, relocalisation or complex formation. These signals are balanced by deubiquitinating
enzymes (DUBs), which antagonize ubiquitination of specific protein substrates.
Because ubiquitination pathways are critically important, DUB activity is often carefully controlled.
USP7 is a highly abundant DUB with numerous targets that plays complex roles in diverse pathways,
including DNA regulation, p53 stress response and endosomal protein recycling. Full-length USP7
switches between an inactive and an active state, tuned by the positioning of 5 Ubl folds in the
C-terminal HUBL domain. The active state requires interaction between the last two Ubls (USP745) and
the catalytic domain (USP7CD), and this can be promoted by allosteric interaction from the first 3 Ubl
domains of USP7 (USP7123) interacting with GMPS.
Here we study the transition between USP7 states. We provide a crystal structure of USP7CD123 and
show that CD and Ubl123 are connected via an extended charged alpha helix. Mutational analysis is used
to determine whether the charge and rigidity of this ‘connector helix’ are important for full USP7 activity.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The covalent attachment of ubiquitin (Ub) to lysines of target
proteins is an important post-translational modification (Hershko
and Ciechanover, 1998; Varshavsky, 2012) that is carried out by a
cascade of E1 activating enzymes, E2 conjugating enzymes and E3
ligases (Passmore and Barford, 2004; Pickart, 2001; Streich and
Lima, 2014). Apart from mono-ubiquitination, ubiquitin can form
chains, by further ubiquitination on any of its seven lysines or the
N-terminus (Komander and Rape, 2012). Different ubiquitination
states, either mono-ubiquitination or different types of poly-
ubiquitination, will have different signalling outcomes for the tar-
get protein; ranging from cellular location to proteasomal degrada-
tion (Hicke and Dunn, 2003; Shabek and Ciechanover, 2010).
To reverse the ubiquitination, deubiquitinating enzymes (DUBs)
can hydrolyse the bond between ubiquitin and the target lysine
(Clague et al., 2013; Komander et al., 2009). Besides functions in
ubiquitin processing and at the proteasome, DUBs can antagonise
the ubiquitination step and affect the cellular fate of the target
protein (Clague et al., 2012). Dysfunction of DUBs can cause an
imbalance in cells and therefore DUBs play important roles ininfectious diseases, cancer and neurological diseases (Hussain
et al., 2009; Nanduri et al., 2013; Todi and Paulson, 2011).
DUBs are specialized isopeptidases that hydrolyse the ubiquitin
bond. In the human genome about 80 different DUBs have been
identified providing specificity for different targets (Nijman et al.,
2005; Clague et al., 2012). These are divided into five classes, based
on their catalytic domain (CD) architecture. Next to this class
defining catalytic domain, DUBs may have a series of regulatory
domains (Reyes-Turcu et al., 2009). These extra domains can confer
substrate specificity, by recruiting the target, but may also influ-
ence the overall activity of the DUB (Sahtoe and Sixma, 2015).
USP7, or HAUSP (Everett et al., 1997), is one of the first DUBs
identified and remains one of the best studied ones (Holowaty
et al., 2003; Wrigley et al., 2011). USP7 is involved in many path-
ways as it deubiquitinates a wide range of targets. It functions in
apoptosis and senescence through its deubiquitinating activity in
the p53 pathway, primarily affecting MDM2 (Brooks and Gu,
2006; Cummins et al., 2004), but also p53 (Li et al., 2002) and
TSPYL5 (Epping et al., 2011). It acts on a large number of targets
in chromatin and DNA regulation, such as H2B (van der Knaap
et al., 2005), Chk1 (Alonso-de Vega et al., 2014), Claspin
(Faustrup et al., 2009), UVSSA (Schwertman et al., 2013), SCML2
(Lecona et al., 2015), DNMT1 (Du et al., 2010), BRCA1-A (Sowa
et al., 2009) and RNF168 (Zhu et al., 2015), but also interacts with
FOXO4 (van der Horst et al., 2006), PTEN (Song et al., 2008),
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viral proteins like ICP0 and EBNA-1 (Holowaty and Frappier, 2004),
making it an interesting but complex protein to study.
USP7 belongs to the family of ubiquitin specific proteases (USP),
which have a papain-like catalytic domain (CD, denoted as USP7CD)
(Hu et al., 2002). USP7 is one of the larger USP family members
with an N-terminal TRAF domain (Fig. 1a), which is critical for
recruitment of its targets like p53 or MDM2 (Saridakis et al.,
2005; Sheng et al., 2006), and on the C-terminal side five
ubiquitin-like (Ubl) domains. These five Ubl domains together
are dubbed HUBL (for HAUSP-Ubl) domain and denoted as
USP712345. Interestingly, proteins like GMPS, DNMT1 (Cheng
et al., 2015) and ICP0 (Holowaty et al., 2003; Pfoh et al., 2015)
interact primarily with Ubl12, while others like MDM2 and p53
(Ma et al., 2010) seem to have a secondary binding site here, show-
ing that different types of interaction and regulation may occur.Fig. 1. The crystal structure of USP7CD123. (a) Schematic overview of USP7 domains and c
‘connector’ helix, spanning from residue 538–562, is here defined as the full a-helix, ste
structures. Domain colours are used for all structural representation of USP7CD123. (b)
‘connector’ a-helix that links the CD to Ubl1.Structural analysis has revealed that the apo structure of USP7CD
has a catalytic triad that is not functional, as the distance between
active site residues is too large (Hu et al., 2002). In the presence of a
covalently bound ubiquitin aldehyde, the catalytic triad is rear-
ranged to generate a catalytically competent state of CD (Hu
et al., 2002). Interestingly, for full activity the C-terminal domains
are required, as the CD on its own showed a hundred-fold decrease
in activity compared to full-length or the USP7CD12345 (Fernández-
Montalván et al., 2007).
Faesen et al. showed that USP7 exists in an equilibrium between
the active and inactive state and that the active state requires the
presence of the Ubl45 domain. Ubl45 can bind to the USP7CD,
which then promotes the interaction between a C-terminal peptide
on Ubl45 that causes a rearrangement of the switching loop on CD
and induces the rearrangement of the catalytic triad into an active
state (Faesen et al., 2011). The equilibrium between the active andonstructs used. Also indicated are the catalytic residues and domain boundaries. The
mming from the CD. The other domain boundaries are based on previously solved
The crystal structure of USP7CD123 reveals a curved architecture of domains and a
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teric activator GMPS (van der Knaap et al., 2005). This protein
binds to Ubl123 but promotes the interaction between CD and
Ubl45, thus shifting USP7 towards the active side of the
equilibrium.
Structural studies have shown that the Ubl domains are
arranged in a 2-1-2 fashion (Faesen et al., 2011). The crystal struc-
ture of the full HUBL domain showed that the 5 Ubl domains can
exist in an extended state, but geometrical restraints indicate that
this domain needs to rearrange to enable interaction with the CD.
This conclusion was supported by SAXS and binding data. Since the
first two (Ubl12) and last two (Ubl45) Ubl domains are connected
to Ubl3 by small linkers, some flexibility between the domains was
proposed. However, how this ‘folding back’ is achieved is not clear
and structures are required that show the arrangement of these
domains relative to the CD.
Here we present a crystal structure of USP7CD123 containing the
CD and the Ubl domains 1, 2 and 3. It shows that the catalytic
domain is connected to the HUBL domain through a 26 amino-
acid a-helical linker. This apparently rigid linker shows how the
first three Ubl domains are positioned relative to the catalytic
domain.We studied the role of this connecting element in position-
ing of the C-terminal domains and were able to show that the rigid-
ity, length and charges on this linkermay affect the activity of USP7.Table 1
Data processing and refinement statistics for the crystal structure of USP7CD123.
USP7CD123
PDB accession code
Space group F222
Cell dimensions
a (Å) 115.18
b (Å) 195.04
c (Å) 219.78
a () 90
b () 90
c () 90
Monomers in ASU 1
Resolution (Å) 48.76–3.40
Outer shell (Å) 3.67–3.40
Beamline ESRF ID14-1
Wavelength (Å) 0.97935
Observed reflections 77,295 (15,487)
Unique reflections 17,198 (3504)
Rmerge 0.061 (0.733)
Multiplicity 4.5 (4.5)
Completeness 99.9 (100)
Mean (I/r(I)) 13.4 (1.9)
N of protein atoms 5352
Rwork (%) 22.2
Rfree (%) 26.7
RMSD from ideality
Bond lengths (Å) 0.008
Bond angles () 1.278
Chiral volume (Å3) 0.071
Ramachandran plot
Favoured (%) 634 (96%)
Disallowed (%) 3 (0%)
Average B-values (Å2) 104.0
Values within parentheses are for the outer resolution shell.2. Materials and methods
2.1. Constructs and mutations
USP7 constructs USP7CD123 (residues 208–882) and USP7CD12345
(res. 208–1102) were cloned into expression vector pGEX-6P-1 (GE
Healthcare) using BamHI and NotI restriction sites based on the
codon-optimised USP7 from Faesen et al., 2011. Mutations were
introduced in USP7CD12345 using site-directed mutagenesis with
overhanging primers.
2.2. Protein expression and purification
USP7 constructs were expressed in Escherichia coli BL21(DE3)
T1R cells using auto-induction medium overnight at 18 C
(Studier, 2005). Cells were pelleted and resuspended in lysis buffer
(50 mM HEPES pH7.5; 250 mM NaCl; 1 mM EDTA; 1 mM DTT).
DNAseI and 0.1 mM PMSF were added prior to lysis using Emulsi-
flex. The lysate was cleared by centrifuging at 20 k G and super-
natant was applied to Glutathione Sepharose 4B beads (GE
Healthcare). After washing the beads, the protein was eluted using
15 mM reduced glutathione and subjected to cleavage using 3C
protease and dialysis versus 10 mM HEPES pH7.5, 50 mM NaCl,
1 mM EDTA, 1 mM DTT. Anion exchange on a PorosQ column (GE
Healthcare) was performed using a salt gradient (50–500 mM
NaCl; 10 mM HEPES pH7.5; 1 mM DTT). Protein fractions were
pooled and concentrated, followed by size exclusion chromatogra-
phy on a Superdex 200 column (GE Healthcare) equilibrated
against 10 mM HEPES pH7.5; 100 mM NaCl; 1 mM DTT. If neces-
sary, a GST FF column (GE Healthcare) was attached to the end
of the gel filtration column to remove residual GST. The peak frac-
tions were analysed by SDS-PAGE and pooled accordingly. Proteins
were concentrated to 10 mg mL1 for assays and up to 25 mg mL1
for crystallization purposes. Generally, 1 L of culture yields 2 mg of
purified protein.
2.3. Crystallization and data collection
USP7CD123 was used at a concentration of 25 mg mL1 in a sit-
ting drop vapour diffusion experiment using 96-well plates at4 C. Crystallization plates were set up using Mosquito (TTP Lab-
tech) with 0.1 lL of mother liquor (15% PEG-3350; 0.2 M Sodium
citrate pH  8.5) and 0.1 lL of protein solution. Crystals appeared
within one week and were flash-frozen in liquid nitrogen after
being cryo-protected in mother liquor supplemented with 20%
ethylene glycol.
X-ray diffraction data could be obtained from a single crystal to
3.4 Å on beamline ID 14-1 at the ESRF, Grenoble, France. The crys-
tal belongs to space group F222 and the data were processed using
XDS (Kabsch, 2010), yielding statistics shown in Table 1.
2.4. Structure determination
The structure of USP7CD123 was solved by molecular replace-
ment using PHASER (McCoy et al., 2007) with search models for
the catalytic domain (PDB code 1NB8; (Hu et al., 2002)) and the
Ubl-domains (2YLM; (Faesen et al., 2011)), split into separate
searches for Ubl12 and Ubl3. The separate solutions were merged
to one monomer in the asymmetric unit. In the resulting electron
density map, the connector helix could be built manually using
COOT (Emsley et al., 2010). The resulting structure was refined,
using PROSMART geometric restraints from the higher resolution
reference structures (Nicholls et al., 2014), in iterative cycles of
maximum-likelihood restrained refinement in REFMAC from the
CCP4 suite (Murshudov et al., 2011; Winn et al., 2011). The model
was further validated and optimised using MolProbity (Davis et al.,
2004) and PDB_REDO (Joosten et al., 2014). The final model had
Rwork and Rfree values of 22.2% and 26.7% respectively.
2.5. Enzyme activity assays
The DUB activity of the USP7 variants was monitored by mea-
suring the increase in fluorescence upon release of the Rhodamine
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tar plate reader (BMG LABTECH GmbH, Germany), with excitation
wavelength 485 nm (±10 nm) and emission at 520 nm (±10 nm).
For Michaelis-Menten analysis, 1 nM enzyme was used to react
with concentrations of substrate as indicated. The initial rates were
plotted against substrate concentration and fitted with a
Michaelis-Menten model using non-linear regression in Prism 6
(GraphPad). These experiments were performed in triplicate on
two different batches of protein.
2.6. Molecular weight determination using MALLS
Purified proteins were run on analytical gel filtration coupled to
Multi-angle Laser Light Scattering (MALLS) detector MiniDawn Tri-
star (Wyatt Technologies, USA). Molecular weights of correspond-
ing peaks were determined with refractive index using manufac-
turer’s software (ASTRA).
2.7. Melting temperature assessment
Stability of wild type protein and mutants was tested using the
Optim 1000 (Avacta, now Unchained Labs, USA). Using an excita-
tion wavelength of 266 nm, scattering at 266 nm and fluorescence
intensity over the spectrum between 300 nm and 400 nm were
measured and analysed as function of the temperature using the
manufacturer’s software. Barycentric fluorescence curves were
plotted using Prism 6 (GraphPad) and used to obtain melting
temperatures.Fig. 2. Comparison of USP7CD123 to USP7 variants. (a) Structural alignment of the
apo structure of USP7CD (purple) and USP7CD of USP7CD123 (gold) yields an RMSD of
0.53 Å. Both have the misaligned catalytic triad, confirming their inactive state. (b)
Michaelis-Menten analysis of enzyme activities on minimal substrate Ub-Rho,
comparing USP7CD12345 with USP7CD and USP7CD123 shows that Ubl45 is necessary
for full activity of USP7. Insert is a magnification of the larger figure. (c)
Superposition of the HUBL structure (2YLM) on either Ubl12 (dark grey) or Ubl3
(light grey) of the USP7CD123 structure. The structural alignment shows an angle of
25, emanating between Ubl2 and Ubl3.3. Results
3.1. USP7CD123 crystal structure
Wewere able to express and purify a USP7 construct comprising
residues 208-882. This construct contains the catalytic domain (CD)
and the first three Ubl domains, from here on referred to as
USP7CD123 (Fig. 1a). We obtained single crystals in a vapour diffu-
sion setup at 4 C with mother liquor of pH > 7, containing multiva-
lent acids. During optimisation sodium citrate was found to yield
the best diffracting crystals, resulting in a dataset diffracting to
3.4 Å (Table 1). The crystal belonged to space group F222 with unit
cell parameters a = 115.2, b = 195.0 and c = 219.8 Å, with a rather
high solvent content (68%) for a singlemonomer of 79 kDa (Table 1).
The structure was solved by molecular replacement using apo
USP7-CD (1NB8; Hu et al., 2002) followed by separate searches
for Ubl12 and Ubl3 (2YLM; Faesen et al., 2011). After manual build-
ing of the connector helix, the model could be refined to R-values of
Rwork = 0.22 and Rfree = 0.27 with good geometry (Table 1). The R-
values are relatively good for a structure at this resolution, probably
thanks to the external restraints generated by ProSmart from the
higher resolution search models (Nicholls et al., 2014).
The failure of molecular replacement using Ubl123 from the
previous structure as a whole, already indicates a conformational
change in USP7CD123 with respect to the crystal structure of the
extended HUBL (2YLM; Faesen et al., 2011). Indeed, the structural
model for USP7CD123 shows the four domains in a curved, crescent-
shaped conformation, where Ubl3 ‘bends’ inwards, back to the cat-
alytic domain (Fig. 1b). This backward bending contrasts with the
extended conformation of the HUBL domain, and results in a glob-
ular overall shape for USP7CD123.
3.2. Structural analysis of USP7CD123
As shown previously USP7CD123 has the low activity that was
observed for the catalytic domain alone (Fig. 2b; Faesen et al.,2011). Accordingly, we observe that the catalytic triad is misa-
ligned, with the active-site cysteine and histidine separated by
more than 10 Å (Fig. 2a). The catalytic domain aligns much better
with the apo structure of USP7CD (1NB8; Hu et al., 2002) separately
(RMSD 0.53 Å on 322 Ca’s) than with the activated ubiquitin-
bound USP7CD (1NBF; Hu et al., 2002) (RMSD 1.34 Å on 314
Ca’s). The main differences with the apo structure are in a series
of loops, that could not be modelled confidently in this low resolu-
tion structure, and the relatively poor density in the b-strands of
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Clerici et al., 2014).
The overall arrangement of the Ubl123 is different from that
observed in the extended state structure of the five Ubl domains
(Fig. 2c, 2YLM; Faesen et al., 2011). When aligning the first two
Ubls, the third Ubl shows a 25 rotation with respect to the
extended structure (Fig. 2c). Such an angle was also observed in
the co-crystal structures of Ubl123 with an ICP0-peptide (Pfoh
et al., 2015) and the structure of HUBL with DNMT1 (Cheng
et al., 2015). Both these structures could exhibit this rotation as
consequence of binding of the protein partner, but the USP7CD123
structure shows that the protein alone can have this flexibility.
The bending of Ubl3 fits with the model proposed (Faesen et al.,
2011), as this curving lessens the gap between the CD and the very
C-terminus, reducing the distance between K882, the last residue
of the construct crystallized, and C223, the active site, to 47 Å. In
this gap, the remaining Ubl45 domain of 45 Å would fit perfectly
(Fig. 2c), keeping in mind the extending, activating C-terminal pep-
tide. As proposed earlier (Pfoh et al., 2015), this distance could be
further bridged by a hinge motion at the region between Ubl3
and Ubl4, an area notoriously flexible, as seen in the full-length
degradation pattern (results not shown and Faesen et al., 2011).
3.3. USP7CD is connected to the Ubl domains by an a-helix
A new finding in the USP7CD123 crystal structure is the long a-
helix connecting the catalytic domain to the Ubl domains
(Fig. 1b). Previous structures have shown parts of the helix (Hu
et al., 2002; Pfoh et al., 2015), and the structure of USP7CD123 con-
firms these helical fragments. This 39 Å helix (26 residues) con-
nects the CD to the HUBL domains, and will be referred to as
’connector helix’ from here onwards. The density for this part of
the protein is relatively well-defined, most probably thanks to
crystal packing and the rigidity in the element. Having two
domains connecting over such a length with a rigid a-helical ele-
ment could imply that the helix has an important function in the
protein. Therefore we analysed whether this connector helix was
important for activity.
3.4. The connector helix is necessary for full USP7 activity
First we studied whether the rigid extended nature of the con-
nector is important for activity. The connector helix’ rigidity can
influence the correct positioning, because such an extended ele-
ment will create distance between the CD and Ubl1. This distance
could be necessary to position the activating C-terminal tail cor-
rectly for folding back onto the catalytic domain and promoting
its activation. In order to investigate the role of the helix, we intro-
duced two ‘bending motifs’ by mutating stretches AQK552 and
EAH560 (Fig. 3a) to proline-glycine-proline in the USP7CD12345 con-
struct, which contains the full HUBL domain.
These USP7CD12345 mutants could be expressed and purified
according to the wild type protocol, although both mutants eluted
later from the gel filtration column (Supplementary Fig. 1a). The
wild type construct dimerises at concentrations above 1 mg/mL,
and with the introduced mutations the dimerization equilibrium
seems to have shifted to higher concentrations (Supplementary
Fig. 1b). Furthermore, melting temperature analysis (Supplemen-
tary Fig. 1c) was performed, resulting in similar values, indicating
the mutants are as stable as wild type protein.
Both AQK552PGP and EAH560PGP were analysed in a deubiqui-
tination assay and compared to wildtype USP7CD12345 (Fig. 3b). The
KM values were similar, but the kcat rates showed interesting differ-
ences (Table 2). The mutant with the bend at the end of the con-
nector helix (EAH560PGP) exhibited similar activity as wildtype.
This would indicate that the HUBL domain has enough intrinsicflexibility to overcome such a bending disruption at the end of
the extending connector helix. In contrast, the mutant with a bend
in the middle of the helix (AQK552PGP) has lower activity, due to a
lower kcat (Table 2, Fig. 3b). The increased flexibility within the
helix may have changed the spatial location of the Ubl domains
with respect to the CD and this could explain why the activation
by Ubl45 is affected.
3.5. A charged patch in the connector helix has influence on USP7
activity
We identified a cluster of charged residues in the connector
helix (K554, R555 and R558) all pointing inwards, towards the cat-
alytic domain. On the complementary surface of the catalytic
domain a similar positive cluster of five lysines was identified
(Fig. 3c). These positive surfaces (with distances between 4 Å and
10 Å) could repel the connector helix away from the catalytic
domain. We wondered if this would be relevant for the activity
of USP7.
We made mutations in the active USP7CD12345 construct that
neutralised (KR554AA R558A) or reverted (KR554AE R558E) the
charge on the linker. These could be expressed and purified in a
similar fashion as wild type USP7CD12345 (Supplementary Fig. 1a),
indicating no drastic changes in fold. When comparing the mutants
with wild type protein in a deubiquitination assay (Fig. 3b), they
showed reduced activity, indicating that the charge has a role in
the activity of USP7. The KM-values are similar for the mutants
and wild type, indicating that these mutants do not affect the bind-
ing of ubiquitin (Table 2). The values for kcat are two-fold lower,
which suggests that the charged patch influences the efficiency
of the Ubl45 domain activation of the CD.
3.6. The connector helix has a minimum length to allow for full activity
Next to the helix’ rigidity and charged patch, the length could
influence the positioning of Ubl45, and thereby the activation.
Therefore, we investigated the length of the connector and its
effect on the activity of the USP7CD12345 construct. To this end we
removed one or two a-helical turns (4 residues per turn) on the
C-terminal (D561-564 and D557-564) as well as the N-terminal
part (D538-541 and D538-545) of the helix (Fig. 3e).
These mutants could be expressed and purified using the
USP7CD12345 protocol and the gel filtration profiles indicated a
monomeric species (Supplementary Fig. 1a). The activity assays
yielded similar KM-values, however the activity of the mutants dif-
fered in kcat (Fig. 3f and Table 2), indicating that the effect is not on
the final positioning, but on the efficiency of reaching this stage. In
agreement with the findings for the mutant EAH560PGP, where the
last helical turn is affected, deletion of one turn does not affect
catalysis. Deletion of a second turn, whether at the start or the
end of the helix, affects the activity as shown by the two-fold lower
values kcat.4. Discussion and conclusions
The large number of important targets reported for USP7 indi-
cates that it has a number of separately regulated functions in
the human cell, but its exact molecular functioning remains elu-
sive. Here we present a partial structure of USP7, which shows
how previously solved crystal structures are connected and allows
near full-length modelling. The crystal structure reveals a long
extended a-helix that connects the CD to the HUBL domain. We
studied the importance of this connector helix and found that it
may play in a role in regulation of activity by positioning the C-
terminal element.
Fig. 3. The connector helix is important for full activity of USP7. (a) Mutations in the connector helix that affect its rigidity were introduced in two locations AQK552PGP
(purple) and EAH560PGP (green). (b) Michaelis menten analysis of mutants that affect the charge or bending of the helix show similar KM-values as wild type USP7CD12345, but
yield differences in kcat. Curve colours are matched throughout the panels as indicated in Fig. 3d. (c) Mutations in the connector helix that affect a charged patch were
introduced. Zoom in on the connector helix and surroundings shows a charged patch on both the connector helix and the CD. (d) Overview of the mutants made, serving as a
legend to all panels in Fig. 3. (e) Zoom in on the connector helix, showing the deleted helix turns on its N-terminal end (red and pink) and the C-terminal end (shades of
green). (f) Michaelis-Menten analysis for deletion mutants show little changes in KM-values, but indicate a decrease in kcat upon removal of 2 helical turns of the connector
helix.
Table 2
Michaelis-Menten analysis of USP7CD12345 constructs.
kcat (s1) KM (lM) kcat/KM (lM1 s1)
WT 2.80 ± 0.04 8.80 ± 0.32 0.32
AQK552PGP 1.69 ± 0.02 8.48 ± 0.28 0.20
EAH560PGP 2.45 ± 0.03 9.47 ± 0.31 0.26
KR554AA R558A 1.10 ± 0.03 7.17 ± 0.54 0.15
KR554AE R558E 1.46 ± 0.05 9.75 ± 0.78 0.15
D538-541 2.47 ± 0.08 9.11 ± 0.86 0.27
D538-545 1.54 ± 0.09 11.86 ± 1.61 0.13
D561-564 2.87 ± 0.07 7.13 ± 0.39 0.40
D557-564 1.03 ± 0.02 6.04 ± 0.34 0.17
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and the length of the connector helix play a role in activation.Mutations in the helical element lead to a modest decrease in kcat,
but do not affect KM. The observed effect is analogous to the
changes seen in the presence of the allosteric activator GMPS,
but in the opposite direction (Faesen et al., 2011; van der Knaap
et al., 2005). In both cases the actual activation has not changed,
but the equilibrium between the active and inactive state has
shifted, in this case towards the inactive state. When this is dis-
rupted, the equilibrium between active and inactive USP7 will shift
as the efficiency of ‘folding back’ onto the CD of Ubl45 is somewhat
disrupted (Fig. 4).
The HUBL domain has some flexibility on its own, as USP7 activ-
ity remains similar for themutant EAH560PGP and upon removal of
an a-helical turn on either side of the connector helix. Only upon
tampering with the charge or removing multiple turns the activity
drops to roughly half the kcat. This suggests that the Ubl45 domain
Fig. 4. Model of USP7 activation. (a) The model of USP7 self-activation shows an equilibrium between the inactive and active state, the transition requiring a rearrangement
of the HUBL domain. (b) A bend within the connector helix of USP7 could change the efficiency of the positioning of Ubl45, affecting the overall activity of USP7. (c) Mutating
the charged patch could have a similar effect, affecting the efficiency of the positioning of Ubl45 and thereby the USP7 self-activation. (d) Shortening of the connector helix
with two helical turns affects the self-activation, possibly due to the efficiency of positioning of Ubl45.
R.Q. Kim et al. / Journal of Structural Biology 195 (2016) 11–18 17is still able to activate the catalytic domain, albeit less efficiently.
The exact positioning of Ubl45 is still unknown, but our mutational
analysis shows that changes in the connector helix play a modest
role in USP7 activity, probably by less efficient positioning of Ubl45.
We know that the linker regions of HUBL are rather flexible, as
they are susceptible to proteolysis in protein purification. The first
linker, between Ubl12 and Ubl3, can allow Ubl3 to make an angular
motion of up to 35 (Pfoh et al., 2015), but most of the kinking
should take place in the second linker, between Ubl3 and Ubl45.
This second pivot point should allow for another 50 to get Ubl45
towards the CD. Distance-wise our structure shows that it can fit,
but the exact interaction spot on the catalytic domain is not known.
Our structure begins to show the flexibility of the linker
between Ubl12 and Ubl3, in line with recent co-crystal structures
of (parts of) the HUBL domain with DNMT1 and ICP0 (Cheng
et al., 2015; Pfoh et al., 2015). The relative bending of Ubl3 in these
structures could have been induced by binding of the protein part-
ner. In the USP7CD123 structure however, we don’t have a binding
partner, suggesting that USP7 does not need a specific modulator
for this ’folding back’ motion.
The HUBL domain is an important regulatory region in USP7. It
contains the second binding site (Ubl12) of targets p53 and MDM,
but where this interaction exactly takes place and whether this
influences the activity on these targets is yet unknown. Ubl12 is
known to bind GMPS, an allosteric activator, as well as DNMT1
(Cheng et al., 2015), URHF1 and ICP0 (Pfoh et al., 2015). The co-
crystal structure of the Ubls with the ICP0 interactor peptide
(4WPH; Pfoh et al., 2015) shows a similar bend of Ubl3 as we found
in the structure of USP7CD123 and this is also seen in the structure
of the full HUBL domain with DNMT1 (4YOC; Cheng et al., 2015).
However, the Ubl45 in this structure has an extended conforma-
tion, and how ‘closing’ of the gap towards the catalytic domain
occurs, an important step in USP7 self-activation, remains unclear.
The changes in kcat observed upon mutation of the connector
helix, and upon GMPS binding to Ubl123 (Faesen et al., 2011) indi-
cate that these regions can be allosterically modulated. One could
imagine that binding of small molecules at these sites could havea function in regulation of USP7 activity. As the charged patch of
the connector helix is required for full activity, this could be a good
starting point for structure-guided inhibitor design in a USP7 speci-
ficmanner, especially as USP7 is emerging as an important drug tar-
get (Colland et al., 2009; Kessler, 2014; Lee et al., 2016; Nicholson
and Suresh Kumar, 2011;Weinstock et al., 2012). Good understand-
ing of the conformational changes and allosteric regulation of this
critical DUB will be important to understand the effects of bound
inhibitors. Our new structure will contribute to these efforts.
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